Health ❯ Healthcare ❯ Immunotherapy

Checkpoint Inhibitors

PD-L1 Inhibition Treatment Resistance Pembrolizumab Tumor Immunology PD-L1 Degraders Tumor Resistance PD-1/PD-L1 Blockade Cadonilimab Nivolumab and Relatlimab Anti-PD-L1 Therapy

Inhibrx Combo Shows 44% Response vs 21% With Pembrolizumab Alone in First-Line Head and Neck Cancer

The early Phase 2 readout supports a move to Phase 3 in Q3 2026.

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

IFITM3 Identified as Key Modulator of Immunotherapy Response in Small Cell Lung Cancer

Chromosomal Instability Drives Treatment Resistance in Metastatic Cancer